focus -WSS

focus

author：entertainment 2025-08-11 09:49:08 - browse：51

Humana sign -- health business coverage from STAT — Humana’s Medicare Advantage business is faring even worse than the company let on last week. Ed Reinke/AP

Humana’s Medicare Advantage business is faring even worse than the company let on last week, with “unprecedented” numbers of older adults getting medical care and busting through its tactics for holding up payment.

The country’s second largest private Medicare insurer disclosed Thursday it’s projecting roughly half the profit in 2024 that investors had expected. The news comes a week after Humana already lowered its projected 2023 profit, which still came in at north of $3 billion before taxes.

The stock market’s punishment was swift and decisive, sinking Humana’s share price by roughly 12% at midday. Outgoing CEO Bruce Broussard worked to calm nerves on the company’s investor call, reiterating his confidence in MA. Humana went all-in on the program when it announced last year it would wind down its employer business, but that comes as regulators are beefing up scrutiny of MA plans.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

leisure time

WSS

STAT letters to the editor on burnt

Personalized medicine goes far beyond genetics

The cancer stories no one wants to hear

How to ethically and practically extend health care to all

Radiology is caught between AI's potential and concern for patients

Roche to buy Carmot Therapeutics, developer of obesity drugs

entertainment

focus

focus

Dobbs anniversary: the lost opportunity of abortion as health care

It costs an awful lot of money to give away a kidney

DIEP, the 'gold standard' of breast reconstruction, is under threat

Patients' immediate access to test results puts radiologists in a bind

Virginia high school admissions case could be legal follow

In diabetes hearing, Sanders takes on a new foe: food makers

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT letters to the editor on burnt

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA needs staff influx to meet gene therapy needs, Marks says

entertainment

The cancer stories no one wants to hear

It costs an awful lot of money to give away a kidney

What causes an itch? Researchers may have solved the mystery

Pharma patents targeted by Biden in move to slash drug prices

'Null' research findings aren't empty of meaning. Let's publish them

Pharma patents targeted by Biden in move to slash drug prices

focus

hotspot

leisure time

explore